Casey McCraw, MD
Urology · Henderson, NVNPI 1336403260
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,796 of the $22,593 with a category attached, or 61.1%. 34 manufacturers reported payments, led by Coloplast at 38.4% of the total. Reporting peaked in 2019 at $9,366 and has fallen 82.5% since, to $1,635 in 2025.
Across 417 payments — averaging $54.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$9K
- Boston Scientific$7K
- Neotract Inc.$3K
- Astellas Pharma US Inc$634
- Sumitomo Pharma America, Inc.$400
- Endo Pharmaceuticals Inc.$362
- plus $2K from 28 others
What the payments were for
- Consulting fees$4002%
- Speaking & faculty fees$1,3256%
- Travel & lodging$3,35415%
- Food & beverage$13,79661%
- Education$3,71916%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 66 | $8,677 |
| Boston Scientific | 175 | $7,014 |
| Neotract Inc. | 23 | $3,184 |
| Astellas Pharma US Inc | 28 | $634 |
| Sumitomo Pharma America, Inc. | 14 | $400 |
| Endo Pharmaceuticals Inc. | 9 | $362 |
| Myriad Genetic Laboratories, Inc. | 8 | $308 |
| Dendreon Pharmaceuticals LLC | 11 | $250 |
| Medtronic | 2 | $177 |
| Johnson & Johnson(2 entities) | 8 | $154 |
| Intuitive Surgical | 1 | $152 |
| Ferring Pharmaceuticals Inc. | 16 | $146 |
| Antares Pharma, Inc. | 9 | $141 |
| Telix Pharmaceuticals | 6 | $139 |
| Teleflex LLC | 3 | $121 |
| 180 Medical, Inc. | 6 | $110 |
| Urogen Pharma, Inc. | 4 | $89 |
| AbbVie(2 entities) | 3 | $57 |
| Accord Healthcare, Inc. | 3 | $52 |
| Axonics, Inc. | 3 | $45 |
| Alnylam Pharmaceuticals Inc. | 2 | $43 |
| Pfizer | 2 | $43 |
| Endo USA, Inc. | 2 | $41 |
| Laborie Medical Technologies Corp. | 2 | $40 |
| Urovant Sciences Inc | 2 | $31 |
| Myovant Sciences Inc. | 1 | $28 |
| Photocure Inc | 1 | $24 |
| Novartis | 1 | $23 |
| Immunitybio, Inc. | 1 | $21 |
| Bayer | 1 | $21 |
| Innovation Technologies Inc | 1 | $20 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $19 |
| SRS Medical Systems, Inc. | 1 | $16 |
| Cycle Pharmaceuticals Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$7,194
- UroLift$2,692
- AMS 700 CXR RTE KIT$2,001
- GENERAL ERECTILE DYSFUNCTION$967
- AMS$452
- GENERAL - THERAPIES$272
- PENILE & TESTICULAR RECONSTRUCTN$181
- XIAFLEX$175
- INTERSTIM$162
- Da Vinci Surgical System$152
- SpaceOAR VUE System - 10mL$127
- GEMTESA$125
- Moses$112
How this compares
$22,593 in reported general payments places this provider in the 85th percentile of 63 urology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiaflexCollagenase Clostridium Hist. | 21 | $278,015 |
| MyrbetriqMirabegron | 67 | $48,942 |
| ElmironPentosan Polysulfate Sodium | 14 | $20,609 |
| Tamsulosin Hcl | 649 | $8,436 |
| Testosterone Cypionate | 121 | $7,423 |
| Testosterone | 51 | $6,595 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 194 | $3,209 |
| Oxybutynin Chloride ErOxybutynin Chloride | 148 | $3,097 |
| Finasteride | 239 | $2,981 |
| Estradiol | 38 | $2,053 |
| Dutasteride | 22 | $1,506 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 54 | $982 |
| Cabergoline | 16 | $838 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 121 | $780 |
| Solifenacin Succinate | 12 | $351 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Endo Pharmaceuticals Inc.Xiaflex | $362 | $278,01521 claims |
| Astellas Pharma US IncMyrbetriq | $634 | $48,94267 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 63 urology providers in Nevada.
Other urology in Henderson
- Guillermo PatinoHenderson$15K
- Scott BaranoffHenderson$7K
- Jeffrey ZapinskyHenderson$7K
- Michael FinkelsteinHenderson$3K
- Adam RussonHenderson$2K
- Ralph LarsenHenderson$2K
- William SteinkohlHenderson$1K
- Eliot HorowitzHenderson$125
- Christopher EvansReno$184K
- Vijay GoliLas Vegas$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.